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Abstract: Nine analogs of 1′S-1′-acetoxychavicol acetate (ACA) were hemi-synthesized and 
evaluated for their anticancer activities against seven human cancer cell lines. The aim of this study 
was to investigate the anti-proliferative, apoptotic, and anti-migration effects of these compounds and 
to explore the plausible underlying mechanisms of action. We found that ACA and all nine analogs 
were non toxic to human mammary epithelial cells (HMECs) used as normal control cells, and only 
ACA, 1′-acetoxyeugenol acetate (AEA), and 1′-acetoxy-3,5-dimethoxychavicol acetate (AMCA) 
inhibited the growth of MDA-MB-231 breast cancer cells with a half-maximal inhibitory concen-
tration (IC
50
) value of 30.0 µM based on 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay results, and were selected for further investigation. DNA fragmentation 
assays showed that these three compounds markedly induced apoptosis of MDA-MB-231 cells. 
Western blot analysis revealed increased expression levels of cleaved PARP, p53, and Bax, while 
decreased expression levels of Bcl-2 and Bcl-xL were seen after treatment, indicating that apop-
tosis was induced via the mitochondrial pathway. Moreover, ACA, AEA, and AMCA effectively 
inhibited the migration of MDA-MB-231 cells. They also downregulated the expression levels of 
pFAK/FAK and pAkt/Akt via the integrin β1-mediated signaling pathway. Collectively, ACA and 
its hemi-synthetic analogs, AEA and AMCA are seen as potential anticancer agents following their 
abilities to suppress growth, induce apoptosis, and inhibit migration of breast cancer cells.
Keywords: 1′S-1′-acetoxychavicol acetate, ACA, ACA hemi-synthetic analogs, triple-negative 
breast cancer, MTT assay, DNA fragmentation, wound-healing assay, Western blot, integrin 
β1 signaling pathway
Introduction
Over the past half-century, natural products presented impressive achievements in 
drug discovery. However, major challenges, such as low production yields of natural 
products during scale-up efforts,1 inadequate natural resources,2 and their complex 
structures that impede improved structural modifications and synthesis of compounds, 
have hindered the development of these natural products as pharmaceutical drugs.3 
In addition, screening of numerous extracts and purified compounds from a variety 
of sources involves substantial expenditure and time. Due to these limitations, it is 
imperative to perform structural modifications on potential compounds through organic 
hemi-synthesis, as this would allow discovery of analogs with higher efficacy.
1′S-1′-acetoxychavicol acetate (ACA) is a phenylpropanoid which can be found in 
the plant Alpinia conchigera (Zingiberaceae).4 It is known to exhibit a broad range of 
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biological properties such as antiulcer,5 antifungal,6 inhibi-
tion of xanthine oxidase,7 inhibition of Epstein–Barr virus 
activation,8 and anticancer activity.9–12 Due to its wide range of 
biological functions, hemi-synthesis of different ACA analogs 
was warranted for enhancement purposes.13 However, various 
anticancer properties, such as anti-proliferative, apoptotic, and 
anti-migration effects of its analogs, are yet to be reported.
Breast cancer is the most common cancer in women in 
many countries, including Malaysia.14 Triple-negative breast 
cancer (TNBC) is one of the subgroups of breast cancer, 
which lacks expression of estrogen receptor (ER), progester-
one receptor (PR), and HER-2.15 It constitutes roughly 15% 
of diagnosed breast cancers,16 and unfortunately, it does not 
respond to the most effective treatments for breast cancer 
such as targeted endocrine therapy.15 Moreover, the aggres-
siveness of TNBC leads to a high number of metastatic cases 
and deaths. Thus, the development of effective anticancer 
drugs for TNBC treatment is crucial.
In this study, the effects of ACA and its hemi-synthetic 
analogs on the proliferation of various cancer cell lines were 
assessed. We also investigated two other major anticancer 
properties, namely apoptosis and anti-migration effects, and 
discussed their underlying molecular mechanisms. We dem-
onstrated that ACA, 1′-acetoxyeugenol acetate (AEA), and 
1′-acetoxy-3,5-dimethoxychavicol acetate (AMCA) could 
inhibit MDA-MB-231 TNBC cell proliferation by inducing 
apoptosis through the regulation of vital proteins, namely 
PARP, p53, Bcl-2, Bcl-xL, and Bax. In addition, our results 
also revealed the potential of these three compounds against 
tumor metastasis by downregulating the expression of pFAK, 
focal adhesion kinase (FAK), pAkt, and Akt via the integrin 
β1-mediated pathway. These observations suggested that 
ACA, AEA, and AMCA may be potential agents in the 
treatment of TNBC.
Materials and methods
general chemistry procedure
Unless otherwise noted, all materials were obtained from 
commercial suppliers and were used without further purifica-
tion. Reaction time and purity of products were monitored 
by thin-layer chromatography on Merck silica gel aluminum 
cards (0.2 mm thickness) with fluorescent indicator at 254 nm. 
Column chromatography was run on silica gel (200–300 
mesh) obtained from EMD Millipore (Billerica, MA, USA). 
All spectral data were obtained using the following instru-
ments: infrared (IR) on a Perkin Elmer RX1 FT-IR spectrom-
eter, ultraviolet (UV) on a Shimadzu UV-160A UV–Visible 
Recording Spectrophotometer. One-dimensional (1D; 1H, 13C, 
distortionless enhancement by polarisation transfer) and two-
dimensional (2D; correlation spectroscopy, nuclear overhauser 
effect spectroscopy, heteronuclear single-quantum coherence 
spectroscopy, heteronuclear multiple-bond connectivity) 
nuclear magnetic resonance (NMR) spectra using CDCl
3
 as 
solvent were recorded on Bruker AVN 400 (400 MHz for 
1H NMR, 100 MHz for 13C NMR) spectrometer. Chemical 
shifts were internally referenced to the solvent signals in 
CDCl
3
 (1H, δ 7.26; 13C, δ 77.0), with tetramethylsilane as the 
internal standard and mass spectrometry (MS) on a Shimadzu 
gas chromatograph-MS spectrometer (HP 6890 Series Mass 
Selective Detector and HP 6890 Series GC System).
isolation of aca
The rhizomes of A. conchigera Griff. were collected from Jeli 
province of Kelantan, East Coast of Peninsular Malaysia.4 
The sample was identified by Prof Dr Halijah Ibrahim 
from the Institute of Biological Science, Faculty of Science, 
University of Malaya. A voucher specimen (KL5049) was 
deposited in the Herbarium of Chemistry Department, 
Faculty of Science, University of Malaya. ACA was isolated 
following our previously published methods.4
general procedure to obtain  
compounds 2–8
4-Allyl-2,6-dimethoxyphenol (2), (S)-α-vinylbenzyl alco-
hol (3), and 4-allyl anisole (5) were purchased from Sigma-
Aldrich Co. (St Louis, MO, USA). Eugenol (4) was purchased 
from Merck & Co., Inc. (Whitehouse Station, NJ, USA). 
Compounds 6, 7, and 8 were synthesized from 2, 3, and 4, 
respectively, by reacting with acetic anhydride (Scheme 1).
general procedure to synthesize 
compounds 17–20
Compounds 17–20 were synthesized by the modification of 
Lee and Ando’s17 procedure.
aea (17)
To a solution of vinylmagnesium bromide freshly prepared 
from magnesium turning (0.24 g, 9.87 mmol), 1 M vinyl 
bromide (6.6 mL, 6.57 mmol) and catalytic amount of iodine 
crystal in dry diethyl ether (20 mL), a solution of aldehyde 9 
(0.50 g, 3.29 mmol) in diethyl ether (10 mL) under ice bath, 
were added. The ice bath was removed, and the mixture was 
allowed to warm to room temperature. After the reaction mix-
ture was stored for 2 h at room temperature, saturated aqueous 
NH
4
Cl (10 mL) solution was added. The mixture was extracted 
with diethyl ether (2×20 mL). The resulting organic extracts 
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were combined, and the solvent was removed under reduced 
pressure to yield a crude product. The oily product (intermedi-
ate 13) obtained by usual workup was acetylated with acetic 
anhydride (0.62 mL, 6.57 mmol) and 4-dimethylaminopyridine 
(DMAP; 0.81 g, 6.64 mmol) in dichloromethane (15 mL) in an 
ice bath. After consumption of starting material and product 
formation, the reaction was quenched with saturated aqueous 
NH
4
Cl (10 mL) solution and extracted with dichloromethane 
(3×15 mL), dried (NaSO
4
), and filtered. Evaporation of filtrate 
gave a yellow oil, which was purified by column chromatog-
raphy on silica gel, and eluting with hexane/ethyl acetate (9:1) 
afforded the desired product as a yellowish oil 17 (0.53 g, 
61%). The synthetic analog 17 is the same as the natural analog 
AEA that was previously studied.18,19
The spectral analysis of the yellowish oil: IR (neat) 
υ
max
, cm−1: 1,767, 1,742, 1,647, 1,607, 1,233, 1,198, 857. 
UV λ
max
, nm: 299.0. 1H NMR (CDCl
3
, 400 MHz), δ: 2.12 
(3H, s), 2.31 (3H, s), 3.84 (3H, s), 5.25 (2H, dd, J =10.5), 
5.99 (1H, m), 6.24 (1H, d, J =5.8), 6.95 (1H, s), 7.02 (2H, d, 
J =7.8). 13C NMR (CDCl
3
, 100 MHz), δ: 20.6 (CH
3
), 21.25 
(CH
3
), 55.9 (OCH
3
), 75.7 (CH), 111.5 (CH), 117.0 (CH
2
), 
119.6 (CH), 122.8 (CH), 135.9 (CH), 137.6 (C), 139.7 (C), 
151.2 (C), 168.9 (C), 169.7 (C). MS m/z (electron ionization) 
40, 45, 61, 77, 91, 107, 121, 264 (M+•). High resolution 
mass spectroscopy m/z (electron ionization): 264.0993 (M+• 
C
14
H
16
O
5
+• requires 264.0998).
aMca (18)
To a solution of vinylmagnesium bromide freshly prepared 
from magnesium turning (0.17 g, 7.14 mmol), 1 M vinyl 
bromide (3.6 mL, 3.5 mmol) and catalytic amount of iodine 
crystal in dry diethyl ether (20 mL), a solution of aldehyde 
10 (0.30 g, 1.65 mmol) in diethyl ether (10 mL) under 
ice bath, were added. The ice bath was removed, and the 
mixture was allowed to warm to room temperature. After 
the reaction mixture was stored for 1 h at room temperature, 
saturated aqueous NH
4
Cl (10 mL) solution was added. The 
mixture was extracted with diethyl ether (2×20 mL). The 
resulting organic extracts were combined, and the solvent 
was removed under reduced pressure to yield a crude product. 
The oily product (intermediate 14) obtained by usual workup 
was acetylated with acetic anhydride (0.33 mL, 3.30 mmol) 
and DMAP (0.41 g, 3.36 mmol) in dichloromethane (15 mL) 
in an ice bath. After consumption of starting material and 
product formation, the reaction was quenched with satu-
rated aqueous NH
4
Cl (10 mL) solution and extracted with 
dichloromethane (3×15 mL), dried (NaSO
4
), and filtered. 
Evaporation of filtrate gave a yellow oil, which was purified 
Scheme 1 schematic preparation of aca analogs.
Abbreviations: aca, 1′S-1′-acetoxychavicol acetate; DMaP, 4-dimethylaminopyridine; rT, room temperature.
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by column chromatography on silica gel, and eluting with 
hexane/ethyl acetate (9:1) afforded the desired product as a 
yellowish oil 18 (0.30 g, 63%).
The spectral analysis of the yellowish oil: IR (neat) 
υ
max
, cm−1: 1,761, 1,645, 1,234. UV λ
max
, nm: 304.5. 1H 
NMR (CDCl
3
, 400 MHz), δ: 2.13 (3H, s), 2.33 (3H, s), 3.81 
(6H, s), 5.31 (2H, dd, J =10.0 Hz), 5.98 (1H, m), 6.21 (1H, 
d, J =5.8 Hz), 6.61 (2H, s). 13C NMR (CDCl
3
, 100 MHz), 
δ: 20.4 (CH
3
), 21.2 (CH
3
), 56.1 (2OCH
3
), 76.0 (CH), 104.0 
(2CH), 117.0 (CH
2
), 128.4 (C), 135.9 (CH), 137.2 (C), 
152.1 (2C), 168.7 (C), 169.9 (C). HRMS m/z (EI): 294.1107 
(M+• C
15
H
18
O
6
+• requires 294.1103).
1′-acetoxy-3,5-dimethoxychavicol (19)
To a solution of vinylmagnesium bromide freshly prepared 
from magnesium turning (0.92 g, 38.3 mmol), 1 M vinyl 
bromide (17 mL, 17.1 mmol) and catalytic amount of iodine 
crystal in dry diethyl ether (30 mL), a solution of aldehyde 
11 (0.98 g, 5.89 mmol) in diethyl ether (10 mL) under ice bath, 
were added. The ice bath was removed, and the mixture was 
allowed to warm to room temperature. After the reaction mix-
ture was stored for 2 h at room temperature, saturated aqueous 
NH
4
Cl (10 mL) solution was added. The mixture was extracted 
with diethyl ether (2×30 mL). The resulting organic extracts 
were combined, and the solvent was removed under reduced 
pressure to yield a crude product. The oily product (inter-
mediate 15) obtained by usual workup was acetylated with 
acetic anhydride (0.60 mL, 6.35 mmol) and DMAP (1.52 g, 
12.4 mmol) in dichloromethane (20 mL) in an ice bath. After 
consumption of starting material and product formation, the 
reaction was quenched with saturated aqueous NH
4
Cl (10 mL) 
solution and extracted with dichloromethane (3×15 mL), dried 
(NaSO
4
), and filtered. Evaporation of filtrate gave a yellow 
oil, which was purified by column chromatography on silica 
gel, and eluting with hexane/ethyl acetate (9:1) afforded the 
desired product as a yellowish oil 19 (0.90 g, 65%).
The spectral analysis of the yellowish oil: IR (CCl
4
) 
υ
max
, cm−1: 1,739, 1,602, 1,558, 1,519, 1,459, 1,232. UV λ
max
, 
nm: 304.5. 1H NMR (CDCl
3
, 400 MHz), δ: 2.11 (3H, s), 3.77 
(6H, s), 5.31 (2H, dd, J =10.5 Hz), 5.97 (1H, m), 6.16 (1H, d, 
J =5.9 Hz), 6.38 (2H, s), 6.49 (1H, s). 13C NMR (CDCl
3
, 
100 MHz), δ: 21.3 (CH
3
), 55.4 (2OCH
3
), 76.8 (CH), 100.0 
(CH), 106.6 (2CH), 141.3 (C), 160.9 (2C), 170.0 (C). HRMS 
m/z (EI): 236.1045 (M+• C
13
H
16
O
4
+• requires 236.1049).
1′-acetoxy-4-methoxychavicol (20)
To a solution of vinylmagnesium bromide freshly prepared 
from magnesium turning (2.14 g, 89.2 mmol), 1 M vinyl 
bromide (37 mL, 37.0 mmol) and catalytic amount of iodine 
crystal in dry diethyl ether (50 mL), a solution of aldehyde 
12 (1.68 g, 12.3 mmol) in diethyl ether (10 mL) under ice bath, 
were added. The ice bath was removed, and the mixture was 
allowed to warm to room temperature. After the reaction mix-
ture was stored for 3 h at room temperature, saturated aqueous 
NH
4
Cl (10 mL) solution was added. The mixture was extracted 
with diethyl ether (2×30 mL). The resulting organic extracts 
were combined, and the solvent was removed under reduced 
pressure to yield a crude product. The oily product (inter-
mediate 16) obtained by usual workup was acetylated with 
acetic anhydride (1.51 mL, 16.0 mmol) and DMAP (3.09 g, 
25.3 mmol) in dichloromethane (25 mL) in an ice bath. After 
consumption of starting material and product formation, the 
reaction was quenched with saturated aqueous NH
4
Cl (10 mL) 
solution and extracted with dichloromethane (3×15 mL), dried 
(NaSO
4
), and filtered. Evaporation of filtrate gave a yellow oil, 
which was purified by column chromatography on silica gel, 
eluting with hexane/ethyl acetate (95:5) afforded the desired 
product as a yellowish oil 20 (1.57 g, 62%).
The spectral analysis of the yellowish oil: IR (neat) 
υ
max
, cm−1: 1,737, 1,515, 1,236. UV λ
max
, nm: 304.5. 1H 
NMR (CDCl
3
, 400 MHz), δ: 2.07 (3H, s), 3.78 (3H, s), 5.28 
(2H, dd, J =10.4 Hz), 5.99 (1H, m), 6.22 (1H, d, J =5.8 Hz), 
6.88 (2H, d, J =6.8 Hz), 7.28 (2H, d, J =6.8 Hz). 13C NMR 
(CDCl
3
, 100 MHz), δ: 21.3 (CH
3
), 55.3 (OCH
3
), 76.3 (CH), 
113.9 (2CH), 116.5 (CH
2
), 128.8 (2CH), 136.4 (CH), 159.5 
(C), 169.1 (C). MS m/z (EI) 43, 65, 77, 91, 104, 121, 131,149, 
164, 206 (M+•). HRMS m/z (EI): 206.0948 (M+• C
12
H
14
O
3
+• 
requires 206.0943).
cell lines and culture conditions
A total of seven human cancer cell lines and one normal cell 
line were used in this study. Five cell lines (PC-3 [prostate 
cancer cells], MCF-7 and MDA-MB-231 [breast cancer 
cells], EJ-28 and RT-112 [urinary bladder cancer cells]) 
were cultured in Roswell Park Memorial Institute (RPMI) 
1640 medium, while two cell lines (HSC-4 [oral squamous 
cancer cells] and HepG2 [liver cancer cells]) were cultured 
in Dulbecco’s Modified Eagle’s Medium (DMEM), supple-
mented with 10% (v/v) fetal bovine serum, 100 U/mL peni-
cillin, and 100 µg/mL streptomycin. The human mammary 
epithelial cell line (HMEC) used as the normal cell control 
was cultured in mammary epithelial growth medium. The 
cell lines such as PC-3, MCF-7, MDA-MB-231, EJ-28, 
HepG2 were obtained from American Type Culture 
Collection (ATCC, Manassas, VA, USA), RT-112 from 
German Collection of Microorganisms and Cell Cultures 
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(Braunschweig, Germany), and HSC-4 from Malaysian 
Cancer Research Initiative Foundation (CARIF, Selangor, 
Malaysia), while HMEC was obtained from Lonza Inc. 
(Allendale, NJ, USA). All cultures were maintained in an 
incubator with humidified atmosphere (5% CO
2
) at 37°C.
cell viability assay
Cytotoxic effects of ACA and its analogs (Figure 1) on the 
seven cancer cell lines were determined by using the in vitro 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) assay. All tested compounds were dissolved 
in dimethyl sulfoxide (DMSO) to a final concentration of 
10.0 mM. In brief, cells were seeded in triplicates on 96-well 
plates at 1.0×104 cells/well. After 24 h, cells were treated with 
increasing concentrations (5.0–50.0 µM) of ACA and its ana-
logs for 24 h. A total of 10.0 µL of MTT reagent (5.0 mg/mL) 
was added to each well. After incubation in the dark at 37°C 
for 2 h, the unreacted MTT dye was removed by aspira-
tion and 200.0 µL of DMSO was added to dissolve MTT 
purple formazan. The absorbance was determined at 579 nm 
by microtiter plate reader (Tecan Sunrise®, Männedorf, 
Switzerland), with a reference wavelength of 650 nm.
Dna fragmentation assay
MDA-MB-231 breast cancer cells were treated with 
ACA, AEA, and AMCA at their half-maximal inhibitory 
concentrations (IC
50
; 4.8, 9.5 and 29.6 µM, respectively) 
for 24 h. Total DNA was extracted from both untreated and 
treated cells using the Suicide Track™ DNA Ladder Isolation 
Kit (Calbiochem, La Jolla, CA, USA) according to the manu-
facturer’s protocol. Analysis of extracted DNA was carried 
out on a 1.0% (w/v) agarose gel electrophoresis and stained 
with ethidium bromide. Observation of DNA fragmentation 
was performed under UV illumination and visualized using 
a gel documentation system (Alpha Innotech, San Leandro, 
CA, USA).
anti-migration assay
The anti-migration effects of ACA and its analogs were 
determined using the wound-healing assay. MDA-MB-231 
cells were seeded in six-well plates and cultured until 80% 
confluent. After an overnight cultivation, complete medium 
was then replaced by serum-free medium treated with 
1 µg/mL mitomycin-C, and the cells were further incubated 
at 37°C for 2 h to stop cell proliferation. A vertical scratch 
was made using a sterile pipette tip across the well, and 
cell debris was removed by washing with 1× phosphate-
buffered saline. Cells were treated with control solvent or 
ACA and its analogs at their 20% inhibitory concentrations 
(IC
20
; Table S1) in serum-free medium. IC
20
 were used 
instead of IC
50
, because IC
20
 were less toxic on the cells. 
Images of wounded cells were captured using an inverted 
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Figure 1 The structures of aca and its analogs (2, 5–8, and 17–20).
Abbreviations: aca, 1′S-1′-acetoxychavicol acetate; aea, 1′-acetoxyeugenol acetate; aMca, 1′-acetoxy-3,5-dimethoxychavicol acetate.
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fluorescence microscope, Nikon Eclipse TS-100 (Nikon 
Corporation, Tokyo, Japan), at 0 and 24 h after wounding. 
The distance between two sides of the wound was analyzed 
using Tscratch software, version 1.0 (The Mathworks, 
Natick, MA, USA).
Western blot assay
MDA-MB-231 cells were treated with ACA, AEA, and 
AMCA and incubated for 24 h. Total proteins were extracted 
using the NE-PER nuclear and cytoplasmic extraction kit 
(Pierce, Rockford, IL, USA) according to the manufacturer’s 
protocol. Protein concentrations were determined using 
the Bio-Rad DC protein assay (Bio-Rad Laboratories 
Inc., Hercules, CA, USA) according to the manufacturer’s 
protocol. Equal amounts of protein were separated by 
sodium dodecyl sulfate polyacrylamide gel electrophoresis 
and transferred to nitrocellulose membranes by semi-dry 
transfer system (Bio-Rad Laboratories Inc.). Membranes 
were blocked with 5% (w/v) bovine serum albumin and 
incubated with primary antibodies against GAPDH, Bcl-2, 
Bcl-xL, Bax, p53, PARP, β1 integrin, FAK, pFAK, Akt, and 
pAkt (1:1,000 dilutions; Cell Signaling Technology, Dan-
vers, MA, USA). Horseradish peroxidase-linked secondary 
antibodies were added, and bound proteins were detected 
through enhanced chemiluminescence reagent (Advan-
sta, Menlo Park, CA, USA) and visualized on a Fusion 
FX7 imaging system (Vilbert Lonmart, Eberhardzell, 
Germany).
statistical analysis
The results were presented as mean ± standard error of the 
mean for triplicates of all experiments. One-way ANOVA 
was used to analyze the statistically significant differences 
with a confidence level of p#0.05.
Results
effect of hemi-synthetic aca analogs on 
the viability of various cancer cell lines
Cytotoxicity evaluation of ACA and its analogs (Figure 1) 
in various human cancer cell lines was performed using the 
MTT assay method with results expressed as mean IC
50
 values. 
Seven cancer cell lines were used in this study to explore 
whether different ACA analogs could exhibit a similar broad 
spectrum cytotoxic effect as was reported for ACA on various 
cancer types.9–12 All tested analogs indicated weak cytotoxicity 
except for compounds ACA, AEA, and AMCA with poten-
cies #30.0 µM (Table 1). Meanwhile, all compounds were 
shown to have minimal cytotoxic activity toward HMECs used 
as normal human breast cell control, indicating nontoxic effects 
against normal cells at therapeutic doses. Solvent control with 
DMSO at #1.0% (v/v) showed insignificant effects on cancer 
cell viability (data not shown), also indicating that cytotoxicity 
was induced as a result of treatment with tested compounds 
instead of DMSO, which is known to be cytotoxic at high 
concentrations.20 ACA induced cytotoxicity on all cancer cell 
lines tested, with highest levels of efficacy being observed in 
breast adenocarcinoma (MDA-MB-231) and oral squamous 
carcinoma cells (HSC-4) at 24 h post treatment time. Although 
AEA and AMCA also induced cytotoxicity, their effects were 
found to be selective toward specific cancer cell lines. AEA 
was found to induce high levels of cytotoxicity in bladder 
adenocarcinoma (EJ-28), hepatocarcinoma (HepG2), and oral 
SCC (HSC-4), while AMCA only showed cytotoxic effects 
against MDA-MB-231 cells (Table 1).
effect of aca, aea, and aMca on Dna 
fragmentation
Next, to determine whether their cytotoxic effects are medi-
ated through apoptosis, we performed DNA fragmentation 
Table 1 ic50 values for aca and its analogs on various cancer cell lines and normal cells
Cell lines IC50 (µM)
ACA 2 5 6 7 8 AEA AMCA 19 20
Breast adenocarcinoma (MDa-MB-231) 4.8±0.4 n/a n/a n/a n/a n/a 9.5±0.3 29.6±5.6 n/a n/a
Breast adenocarcinoma (McF-7) 30.0±0.3 n/a n/a n/a n/a n/a 25.2±0.6 n/a n/a n/a
Bladder carcinoma (rT-112) 14.1±3.8 n/a n/a n/a n/a n/a 10.9±2.4 n/a n/a n/a
Bladder carcinoma (eJ-28) 8.2±0.9 n/a n/a n/a n/a n/a 4.2±2.2 n/a n/a n/a
Prostate carcinoma (Pc-3) 26.7±2.3 n/a n/a n/a n/a n/a 13.8±0.8 n/a n/a n/a
Oral squamous carcinoma (hsc-4) 5.5±0.5 n/a n/a n/a n/a n/a 5.1±0.2 n/a n/a n/a
hepatocyte carcinoma (hepg2) 18.0±0.8 n/a n/a n/a n/a n/a 4.3±0.5 n/a n/a n/a
hMecs n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Notes: cells were treated with the test compounds for 24 h. Data are reported as mean ± seM (n=3). n/a denotes that cell viability levels were maintained above 50% at 
maximum concentration of test compound (50 µM) at 24 h of incubation.
Abbreviations: aca, 1′S-1′-acetoxychavicol acetate; aea, 1′-acetoxyeugenol acetate; aMca, 1′-acetoxy-3,5-dimethoxychavicol acetate; hMecs, human mammary 
epithelial cells; ic50, half-maximal inhibitory concentration; seM, standard error of the mean; n/a, not applicable.
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assays. As shown in Figure 2, DNA from the untreated 
group showed no degradation, whereas DNA laddering was 
observed in MDA-MB-231 cells that were treated with ACA, 
AEA, and AMCA at their IC
50
. This typical oligonucleosomal 
DNA degradation is one of the hallmarks of apoptotic cell 
death, thus suggesting that ACA, AEA, and AMCA induce 
cell death through apoptosis.
effect of aca, aea, and aMca on ParP, 
p53, and Bcl-2 family members
To further verify the occurrence of apoptosis induced 
by ACA, AEA, and AMCA on MDA-MB-231 cells, we 
performed PARP cleavage analysis, a common marker 
for induction of apoptosis.21 As shown in Figure 3A, the 
cleavage of full-length PARP enzymes (116 kDa) into an 
89 kDa subunit protein was observed in the MDA-MB-231 
cells that had been treated with ACA, AEA, and AMCA 
at their IC
50
. Based on densitometry analysis, these three 
compounds increased the cleavage of PARP by 7.8-, 4.8-, 
and 1.8-fold compared to untreated cells, respectively 
(Figure 3B). ACA, AEA, and AMCA were also found to 
decrease Bcl-2 and Bcl-xL anti-apoptotic protein levels and 
increase the expression levels of p53 and pro-apoptotic Bax. 
As shown in Figure 3C and D, treatment with ACA, AEA, 
and AMCA at their IC
50
 for 24 h significantly decreased 
the expression level of Bcl-2 by ~40%–50% and Bcl-xL 
by ~30%–50% when compared to untreated cells. The 
p53 levels in MDA-MB-231 cells increased by 3.3-, 3.4-, 
and 2.3-fold after treatment with ACA, AEA, and AMCA, 
respectively (Figure 3E). The three compounds upregulated 
the expression of pro-apoptotic Bax by 6.2-, 9.4-, and 2.9-
fold, respectively (Figure 3F). Collectively, this suggests 
that PARP, p53, Bcl-2, Bcl-xL, and Bax were involved in 
inducing apoptosis via the intrinsic pathway when treated 
with ACA, AEA, and AMCA.
effect of hemi-synthetic aca analogs on 
anti-migration of MDa-MB-231 cells
Cell migration is an important step in the metastatic process.22 
Therefore, the effects of ACA and its analogs on cell migra-
tion were also examined on breast cancer MDA-MB-231 
cells (Figures 4 and S1). This cell line was chosen for 
anti-migration study due to its highly aggressive and strongly 
metastatic properties among the selected panel of cell 
lines.23,24 Our data showed that ACA, AEA, and AMCA and 
compounds 5–8 and 19–20 significantly inhibited the migra-
tion rate of MDA-MB-231 cells compared with untreated 
cells. Furthermore, results revealed that the difference in 
inhibition of cell migration between untreated cells and 
cells treated with DMSO was insignificant (p-value .0.05), 
suggesting that the anti-migration effects seen were not due 
to the solvent.
effect of aca, aea, and aMca on 
downregulators of integrin β1
In addition to anti-proliferative effects and induction of 
apoptosis, ACA, AEA, and AMCA also showed significant 
anti-migration effects on MDA-MB-231 breast cancer cells. 
Thus, the molecular mechanism related to the anti-migration 
effects of these compounds was also investigated. The effect 
of these compounds on the expression of integrin β1, which 
is a major player in tumor metastasis that mediate the adhe-
sion of cells on extracellular matrix (ECM),25 and some of its 
downstream molecules were determined. We examined the 
integrin-mediated pathway on MDA-MB-231 breast cancer 
cell line by Western blot analysis and found that the level 
of integrin β1 decreased following ACA, AEA, and AMCA 
treatment (Figure 5A). Upon integrin β1 binding to ECM, 
the downstream signaling molecules such as FAK and Akt 
were phosphorylated26 and participated in the regulation of 
cell migration. In analyzing the integrin-induced signaling 
pathway, phosphorylation of FAK and Akt was significantly 
reduced by ACA, AEA, and AMCA after 24 h (Figure 5A). 
As shown in Figure 5B, the integrin β1 levels of MDA-MB-231 
0
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Figure 2 agarose gel electrophoresis of Dna in MDa-MB-231 cells treated with 
aca, aea, and aMca.
Notes: cells were untreated (lane UT) or treated with DMsO 0.08% (v/v), aca, 
aea, aMca at their ic50 (4.8, 9.5, and 29.6 µM, respectively) for 24 h. left lane (M) 
shows Dna size markers. cellular Dna was extracted and subjected to agarose 
gel electrophoresis.
Abbreviations: aca, 1′S-1′-acetoxychavicol acetate; aea, 1′-acetoxyeugenol ace-
tate; aMca, 1′-acetoxy-3,5-dimethoxychavicol acetate; DMsO, dimethyl sulfoxide; 
Dna, deoxyribonucleic acid; ic50, half-maximal inhibitory concentration; UT, 
untreated.
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cells decreased by 15.5%, 37.1%, and 93.3% after treatment 
with ACA, AEA, and AMCA, respectively. The reduction 
level of phosphorylated FAK and Akt by ACA, AEA, and 
AMCA was about 70%–94% (Figure 5C and D).
Discussion
ACA is a natural product that exerts anticancer effects by 
inducing apoptosis27 and cell cycle arrest4 and inhibiting 
angiogenesis28 and metastasis.29 Wang et al29 showed that 
ACA exerted cytotoxic effects and inhibited the signal 
transduction pathway related to tumor metastasis, such as 
signal transducer and activator of transcription 3 (STAT3), 
Src homology region 2 domain-containing phosphatase 1 
(SHP-1), and matrix metalloproteinase (MMP)-mediated 
pathway. In this study, ACA inhibited the growth of MDA-
MB-231 cells with IC
50
 of 4.8 µM on the breast cancer cell 
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Figure 3 effects of aca, aea, and aMca on the apoptotic pathway.
Notes: expression levels of ParP, p53, Bcl-2, Bcl-xl, and Bax proteins from MDa-MB-231 cells were analyzed via Western blot analysis (A). gaPDh was used as a loading 
control. The quantitative data (B–F) are presented as mean ± seM from three independent experiments (*p#0.05 by two-tailed unpaired t-test).
Abbreviations: aca, 1′S-1′-acetoxychavicol acetate; aea, 1′-acetoxyeugenol acetate; aMca, 1′-acetoxy-3,5-dimethoxychavicol acetate; Bax, Bcl-2-associated X protein; 
Bcl-2, B-cell lymphoma 2; Bcl-xl, B-cell lymphoma-extra large; DMsO, dimethyl sulfoxide; gaPDh, glyceraldehyde 3-phosphate dehydrogenase; ParP, poly(aDP-ribose) 
polymerase; p53, tumor suppressor p53; seM, standard error of the mean.
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Figure 4 effects of aca and its analogs on the cell migration of MDa-MB-231 cells.
Notes: cells were wounded and treated with DMsO 0.08% (v/v), aca, and nine analogs at ic20 for 24 h. The open wound area at 24 h was quantified using TScratch software 
relative to wound area at 0 h. The mean percentage of area migrated ± SEM from three separate experiments is illustrated. Statistically significant differences were compared 
between untreated conditions versus treatment groups with (*) denoting p-values #0.05.
Abbreviations: aca, 1′S-1′-acetoxychavicol acetate; aea, 1′-acetoxyeugenol acetate; aMca, 1′-acetoxy-3,5-dimethoxychavicol acetate; DMsO, dimethyl sulfoxide; 
ic20, 20% inhibitory concentration; seM, standard error of the mean.
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Figure 5 effects of aca, aea, and aMca on the migration pathway.
Notes: expression levels of integrin β1, FaK, pFaK, akt, and pakt proteins from MDa-MB-231 cells were analyzed via Western blot analysis (A). gaPDh was used as a 
loading control. The quantitative data (B–D) are presented as mean ± seM from three independent experiments (*p#0.05 by two-tailed unpaired t-test).
Abbreviations: aca, 1′S-1′-acetoxychavicol acetate; aea, 1′-acetoxyeugenol acetate; akt, protein kinase B; aMca, 1′-acetoxy-3,5-dimethoxychavicol acetate; DMsO, 
dimethyl sulfoxide; FaK, focal adhesion kinase; gaPDh, glyceraldehyde 3-phosphate dehydrogenase; integrin β1, integrin subunit beta 1; pakt, phosphorylated protein kinase B; 
pFaK, phosphorylated focal adhesion kinase; seM, standard error of the mean.
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line, which is about 10 times lower than Wang et al’s study. 
The significant difference of the results may be due to the het-
erogeneity of cancer cells30 and the changes that occurred in 
cells during cultivation in different laboratory conditions.
Even though ACA was seen to induce apoptosis and 
inhibit migration on some cancer cell types, the apoptotic 
induction and anti-migration mechanisms of hemi-synthetic 
ACA analogs on breast cancer cells have never been reported. 
In this study, we revealed that not only ACA but also two of 
its analogs were able to induce apoptosis and suppress the 
migration of MDA-MB-231 breast cancer cells.
In this study, three compounds (ACA, AEA, and AMCA) 
possessed 1′-acetoxyl group and showed better cytotoxicity 
than other compounds. This highlighted the importance of 
1′-acetoxyl group in governing anti-proliferative activity. 
The absence of the 1′-acetoxyl group (compounds 2, 5, 6, 8) 
could lead to a reduction in inhibitory effects on cancer 
cell growth. These findings are consistent with the study 
by Murakami et al.13 On the other hand, AMCA, which 
possesses an additional methoxyl group at the 5-position 
compared to AEA, exerted a weaker effect against MDA-
MB-231 cells, suggesting that the presence of an additional 
methoxyl group at 5-position may reduce cytotoxic activity. 
In a study by Xu et al,31 the authors reported the structural 
factors of ACA that regulate tumor cell viability, intracel-
lular glutathione level, and glutathione reductase activity in 
Ehrlich ascites tumor cells. They suggested that the acetoxyl 
group substituted at para position of the benzene ring was 
essential, and similarly we found that analog without an 
acetoxyl group at the 4-position (such as compounds 2 and 
20) showed insignificant cytotoxic effects.
MDA-MB-231 was reported as the most sensitive cell 
line toward the compounds tested in terms of cytotoxicity 
and was thus selected as a model for further investigation. 
Another type of breast cancer cell, MCF-7 cell line, was only 
sensitive to ACA and AEA. Despite both cell lines being 
breast cancer cell lines, MDA-MB-231 is a triple-negative 
(lack of ER, PR, and HER-2 expression) breast cancer cell 
line, while MCF-7 is an ER- and PR-positive breast cancer 
cell line. Thus, these differences could be the underlying 
cause toward response variations and drug sensitivity.32
DNA fragmentation is a cellular hallmark of apoptosis. 
In apoptotic cells, endonucleases cleave DNA into internu-
cleosomal fragments of roughly 180–200 bp.33 Since ACA, 
AEA, and AMCA showed active anti-proliferative effects 
and induced internucleosomal DNA fragmentation on MDA-
MB-231 cells, induction of apoptosis was confirmed. During 
the apoptotic process, proteolytic cleavage of PARP due to 
the activation of caspase-334 was seen in this study. Previous 
study showed that ACA induced apoptosis via the activation 
of caspase-3-like activity.35 Thus, the alteration of PARP by 
ACA, AEA, and AMCA was in agreement with the induction 
of apoptosis via the activation of caspase-3. The activation 
of the p53 protein is also related to induction of apoptosis36 
and regulation of Bcl-2 family members’ expression.37 Anti-
apoptotic proteins, Bcl-2 and Bcl-xL, act as inhibitors of the 
mitochondrial intrinsic pathway that block the release of cyto-
chromes and counteract the effects of pro-apoptotic proteins 
such as Bax.38 Pro-apoptotic protein, Bax, redistributes from 
the cytosol to mitochondria during apoptotic events39 to 
cause dysfunction of the mitochondrial membrane.40 In this 
study, the expression of Bax was increased by treatment with 
ACA, AEA, and AMCA, while the expression of Bcl-2 and 
Bcl-xL was decreased. These observations suggested that 
the induction of apoptosis by ACA, AEA, and AMCA was 
triggered by the upregulation of pro-apoptotic proteins and 
downregulation of anti-apoptotic proteins related to the mito-
chondrial intrinsic pathway. Furthermore, previous studies 
showed that ACA and AEA suppressed the growth of cancer 
cells by inhibiting nuclear factor-κB (NF-κB) pathway.19,41–43 
The expression of the anti-apoptotic proteins, such as Bcl-244 
and Bcl-xL,45 was regulated by NF-κB. Hence, the induction 
of apoptosis by ACA, AEA, and AMCA may also be linked 
to the inactivation of the NF-κB.
ACA has also been reported to inhibit metastasis and inva-
sion on different cancer cell types, such as breast cancers,29 
oral cancers,43 prostate cancers,28 and lung cancers.46 These 
investigations point out that ACA may generally suppress cell 
migration and invasion in various cancer cell types. In this 
study, we reported that ACA and its analogs exhibit anti-
migration effects on MDA-MB-231 cells. Although some of 
the ACA analogs showed poor potency against cancer cell 
proliferation, they exhibited strong effects against migration 
and thus reignite interest for further studies on the molecular 
mechanisms governing anti-migration activity of ACA and 
its analogs. In this study, most of the hemi-synthetic ACA 
analogs were not cytotoxic within the 5.0–50.0 µM dose 
range, but many of them were able to inhibit cancer cell 
migration with nontoxic concentrations. Hence, the anti-
migration activity of the ACA analogs is not linked to their 
direct cytotoxic effects on cancer cells. The inhibition of cell 
migration by the compounds occurred at concentrations lower 
than those that inhibited cell proliferation. The difference in 
effective concentrations suggested that different mechanisms 
may be involved to promote ACA analogs’ anti-migration 
effects versus cytotoxic ability.
Cancer cell motility by metastasis is a main step for the 
progression of malignancy.47 Tumor cells take multisteps 
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to metastasize from their initial site to secondary organs by 
migration through basement membranes and extracellular 
matrices.48 The migration process is stimulated extracel-
lularly and initiated by integrins and intracellular signaling 
proteins located at the sites of focal adhesion assembly and 
disassembly.49 Regulating integrin β1 signaling of FAK 
through modulation of Akt activity could lead to inhibition 
of cell migration.50 Many human malignant cancers show 
increased FAK expression promoted by integrin β1 to result 
in increased metastasis.51 In this study, breast cancer cells 
treated with ACA, AEA, and AMCA suppressed integrin 
β1 after 24 h (Figure 5), which indicated their ability to 
interrupt the integrin signaling pathway. Since integrin acts 
as the activator of FAK, we examined the effect of these 
compounds on the activation of pFAK. Upon treatment, 
FAK phosphorylation was significantly reduced in MDA-
MB-231 cells. ACA, AEA, and AMCA also decreased 
Akt phosphorylation, showing that the activity of pAkt 
was correlated with FAK phosphorylation. Thus, rela-
tive intensities of integrin β1, pFAK/FAK, and pAkt/Akt 
showed that ACA, AEA, and AMCA showed anti-migration 
potency and is dependent, at least in part, on the integrin 
β1-mediated signaling pathway. Wang et al29 showed that 
inhibition of metastasis by ACA is through interference with 
the STAT3 signaling pathway. Their findings support our 
current result as STAT3 proteins are known to be interrelated 
to integrin β1. Nevertheless, the mechanism(s) in which ACA 
and its analogs participate in to achieve their anticancer role 
on TNBCs will require further in-depth investigation, such 
as the evaluation of key proteins involved in other metastatic 
signaling pathways.
In addition, the efficacy of ACA is also being studied for 
its use in combination studies with other drugs/biologics. For 
example, ACA reduced tumor volume and side effects in vivo 
when used in combination with alpha-fetoprotein (AFP).52
While stand-alone doses of the analogs may not seem 
clinically relevant at this stage, such structural modifications 
of ACA could potentially serve as a platform to find better 
candidates which can be used in combination regimens during 
preclinical developmental studies. This study demonstrates 
that there is still room for improvement in designing modified 
ACA analogs with increased anticancer activities.
Conclusion
We have identified that ACA, AEA, and AMCA significantly 
inhibited growth, induced apoptosis, and suppressed migra-
tion of human breast cancer cells. Overall, these preliminary 
results revealed that the anti-proliferative activities are not 
absolutely required for the suppression of migration in cancer 
cells by ACA and its analogs. In addition, analogs active in 
anti-proliferation against selected cancer cells were seen to 
possess better anti-migration ability against breast cancer 
cells compared to the natural product itself. Thus, this study 
demonstrates that there is still room for improvement in 
designing new analogs with increased anticancer activities. 
However, more investigations are required to identify the 
different targets of such ACA analogs at the molecular level 
and validate the molecular mechanisms in animal models 
for effective treatment of breast cancer. Overall, this study 
suggested that ACA, along with its hemi-synthetic analogs, 
AEA and AMCA, are potential combinatory therapeutic 
agents for the treatment of TNBCs.
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Supplementary materials
Table S1 ic20 values for aca and its analogs on MDa-MB-231 cell line
IC20 (µM)
ACA 2 5 6 7 8 AEA AMCA 19 20
2.0 48.0 32.0 50.0 31.0 50.0 4.0 12.0 28.0 45.0
Note: ic20 for each analog was used to treat MDa-MB-231 cells for wound-healing assay.
Abbreviations: aca, 1′S-1′-acetoxychavicol acetate; aea, 1′-acetoxyeugenol acetate; aMca, 1′-acetoxy-3,5-dimethoxychavicol acetate; ic20, 20% inhibitory concentration.
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Figure S1 representative pictures of wound-healing assay of MDa-MB-231 cells after various treatments of aca and its analogs at ic20.
Notes: The open wound area at 24 h was quantified using TScratch software relative to wound area at 0 h. All data are presented as mean ± seM from three independent 
replicates, with representative images at 40× magnification shown from each treatment group.
Abbreviations: aca, 1′S-1′-acetoxychavicol acetate; aea, 1′-acetoxyeugenol acetate; aMca, 1′-acetoxy-3,5-dimethoxychavicol acetate; DMsO, dimethyl sulfoxide; 
ic20, 20% inhibitory concentration; seM, standard error of the mean.
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